Join us for session highlights from RheumNow Live 2023.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Preclinical RA – To Treat or Not To Treat
Kevin Deane, MD
University of Colorado
Year of the JAKi
Stanley Cohen, MD, University of Texas
Southwestern Medical School
Fibroblast/Stromal Cells
Michael Brenner, MD
Brigham and Women’s Hospital
Harvard Medical School
Predicting Palindromic Prognosis
A Step Closer to Identifying Phenotypes of RA ILD
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
Giant Cell Arteritis and Polymyalgia Rheumatica Update
JAK Inhibitors for New Indications
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
JAK Inhibitors for New Indications
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Treat to Target Outcomes in Early AxSpA
Does Telemonitoring in SpA Work?
PsA Treatment: is Earlier Better?
JAK Inhibitors for New Indications
Transition from Psoriasis to PsA: Can we Prevent It?
EULAR 2024 Daily Recap - Days 1 & 2
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Voclosporin and Steroids in Lupus Nephritis
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive